Roy Exum: My Pimples And Andrea Sloan

Monday, September 30, 2013 - by Roy Exum
Roy Exum
Roy Exum

A real long time ago I was having a fit with acne. I was a lovelorn teenager, infatuated with pretty girls in a dizzy game where pimples can really become cumbersome. It seemed like nothing was working and, after I grew a pimple large enough for its own zip code, I finally found a genius doctor who quickly became my lifelong hero when he came up with a marvelous idea.

At the time there was a new “super drug”  that was languishing through years of “clinical trials” in the United States and nobody could get any, despite the fact the revolutionary medicine was already available in Germany. My hero called up a close friend who was a German doctor and – presto! – the first 250 pills came flying across the ocean.

I had to promise that I would not sue anybody if I grew an extra set of ears, developed female breasts, or my eyes turned yellow, but, honestly, I would have dyed my hair green to get the American-made medicine. After I took a course of what was then identified by only a strange laboratory number, my pimples and my acne were gone forever. I had Clark Gable looks and never looked back. That’s a true story (except the Gable part.)

Other fellow Americans had to wait for many months. I don’t believe that's right. Since this occurred in my formative years, I have cursed the federal Food and Drug Administration for much of my adult life because the “clinical trials” process we use is horribly dysfunctional and in critical need of an overhaul.

To illustrate my point, allow me to introduce a beautiful Texas lawyer, Andrea Sloan. Yes, she is quite pretty but “beautiful” because her career has been as the executive director of a Texas advocacy project that provides free legal services to low-income victims of domestic or sexual abuse.

Andrea is a victim herself, not just of stage 3c ovarian cancer but a horribly-tangled FDA system. Her doctors have exhausted every known method to save her life. Six years of surgery, radiation, and chemotherapy haven’t worked. She’s still very much a patient at the world-famous M.D. Anderson Medical Center and her oncologist believes an experimental drug called “BMN 673” might well save Andrea’s life.

M.D. Anderson has a good supply of BMN 673 on hand but with millions of dollars at stake, the manufacturer, BioMarin in California, has said no. “It would be unethical and reckless to provide end-stage refractory ovarian cancer patients outside clinical trial with BMN 673 at this early stage of development,” said spokesperson Debra Charlesworth.

“If we did,” Charlesworth explained to CNN, “we would be exposing the experimental drug to a large group without adequate testing. There have been previous circumstances where early access to large groups has resulted in adverse consequences that were worse than the course of the disease.”

I am certain no scientist can hardly wait for somebody to try to explain to me what “adverse consequences” could possibly be worse than what Andrea Sloan is facing without BMN 673. Andrea is pleading for the drug – let the petals of the flower fall where they may – and probably understands the risks as much as anyone involved. She knows what will happen if she fails to get BMN 673 better than anyone else, too.

Here is what she wrote in a statement to the drug company: “I recognize the importance of weighing the risk and the myriad of considerations they face as a company. However, this is a risk worth taking. I will thank them. My family will thank them. An amazing army of loyal supporters, to whom I owe a debt of gratitude, will thank them. In America we do not leave our wounded warriors on the battleground. BioMarin, please be the Calvary that saves me.”

Her M.D. Anderson doctors believe Andrea is a great candidate. Further, the FDA itself has just announced Ms. Sloan qualifies for a “compassionate care” waiver in the rules but the manufacturer, BioMarin, still says no. The word is BioMarin stands to make about $500 million on the drug and, even though they say they plan to give away 10 percent of the medicine to charity, they refuse to face the ethical dilemma.

As of Sunday afternoon Andrea had almost 170,000 supporters on her Change.org webpage and politician Newt Gingrich, co-host of CNN’s “Crossfire” program, is irate at “a corporation protecting its wallet at the expense on Andrea’s possibly dying. If you want to know why big companies often get bad names, it’s explaining that clerical support to fill out FDA paperwork is too difficult when you can save a life.”

Dr. Charles Levenback, Andrea’s doctor, is disappointed at BioMarin’s stance but, as a man who sees the fight against cancer every day, he told CNN reporters, “My own belief is that the drug companies, the manufacturers, the insurance companies, the providers like my hospital M.D. Anderson, the individual medical professionals, the investigators, the patients -- everybody wants the same things. Safe, effect, novel therapies for as many people as it's appropriate for. Even BioMarin, I believe. I don't think this is like 'Let the masses eat cake.' I think they're on the same mission. But the whole system is giving this dysfunctional result."

On Andrea Sloan’s Facebook page there is a picture that tells of “Three Simple Rules.” The text reads, “If you don’t go after what you want in life, you will never have it. If you don’t ask, the answer will always be No. If you don’t step forward, you’ll always be in the same place.”

Those three rules got rid of my pimples but all we can do is pray for Andrea Sloan. She needs it right now.

royexum@aol.com


Farm To Table To Dollars

I recently hosted a discussion with local business leaders, Andy Berke, mayor of Chattanooga, and Heather McTeer Toney, southeast regional administrator for the U.S. Environmental Protection Agency. We had an important conversation about the role of the business community in combating climate change. As the owner of 212 Market Restaurant in downtown Chattanooga, I’ve experienced ... (click for more)

Small Business Makes Chattanooga A Hot Spot For Economic Development

We are fortunate to live in a city experiencing significant economic  growth. From VW’s recent expansion announcement to Coca Cola Bottling’s decision to redevelop the former Olan Mills property in the Shepherd community, Chattanooga is beginning to see a renaissance in job creation that could mirror the redevelopment renaissance we experienced in downtown. As an economic ... (click for more)

Person Shot Sunday Morning On Englewood Avenue

One person was shot on Sunday morning in North Chattanooga. At approximately 9:18 a.m., the Chattanooga Police Department responded to a gunshot wound call at 1049 Englewood Ave. involving one victim. T he victim was transported to a local hospital suffering from a non-life-threatening gunshot wound. Chattanooga Police ask anyone with information regarding ... (click for more)

North Carolina Man Dies In Rafting Incident On The Ocoee River

A 50-year-old North Carolina man died Saturday morning when the raft he was aboard overturned in the Ocoee River. The victim was Gary Brown of Clayton. Mr. Brown and five other occupants along with a guide were ejected after the raft they were navigating overturned in a rapid.   The victim was unresponsive when he was recovered from the water further ... (click for more)

Moc Golfers Finish 10th At Tar Heel Intercollegiate

The Chattanooga Mocs men’s golf team finished 10th at the Tar Heel Intercollegiate today. The Mocs shot 871 over their 54 holes to end up ahead of Charlotte and Mercer in 11th and 12th, respectively. “We’re not pleased with this finish, but we are making progress,” said coach Mark Guhne. “We just didn’t get the low round on the second or third day. If we get that low round, we ... (click for more)

Lady Mocs Soccer Loses 6-0 At Vanderbilt

University of Tennessee at Chattanooga freshman keeper Hannah Dunn (Cookeville, Tenn.) made 16 saves in the Mocs 6-0 loss to Vanderbilt Sunday afternoon at the Vanderbilt Soccer/Lacrosse Complex. “Hannah was amazing,” UTC head coach J.D. Kyzer “There may have been just one or two shots that came right to her, but every other one she had to make the save and she showed up big.” ... (click for more)